FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2970429881> ?p ?o ?g. }

• W2970429881 endingPage "3142" @default.
• W2970429881 startingPage "3142" @default.
• W2970429881 abstract "The human epidermal growth factor receptor 2 (HER2) represents one of the most studied tumor-associated antigens for cancer immunotherapy. The receptors for HER2 are overexpressed in various human cancers, such as breast and ovarian cancer. The relatively low expression of this antigen on normal tissues makes it a clinically useful molecular target for tumor imaging and targeted therapy. HER2 overexpression is correlated with aggressive tumor behavior and poor clinical outcomes. Thus, HER2 has become an important prognostic and predictive factor, as well as a potential molecular target. Due to the heterogeneity of breast cancer and possible discordance in HER2 status between primary tumors and distant metastases, assessment of HER2 expression by noninvasive imaging is important. Molecular imaging of HER2 expression may provide essential prognostic and predictive information concerning disseminated cancer and aid in the selection of an optimal therapy. Another tumor-specific antigen is MUC1, which is silent on normal tissues, but overexpressed in almost all human epithelial cell cancers, including >90% of human breast, ovarian, pancreatic, colorectal, lung, prostate, and gastric cancers and is a promising tumor antigen with diagnostic as well as the therapeutic potential of cancer. Radiolabeled small peptide ligands are attractive as probes for molecular imaging, as they reach and bind the target receptor efficiently and clear from blood and non-target organs faster than bulky antibodies. In this study, HER2 and MUC1-based peptides were synthesized and preclinically evaluated in an effort to develop peptide-based SPECT radiopharmaceuticals derived from tumor-associated antigens for the detection of breast cancer. Our findings demonstrate that the tumor antigen peptides radiolabeled efficiently with 99mTc and showed high metabolic stability in human plasma in vitro. The data from breast tumor cell binding confirmed the high affinity (in low nanomolar range) towards respective breast cancer cell lines. In healthy mice, 99mTc-labeled peptides displayed favorable pharmacokinetics, with high excretion by the renal system. In tumor xenografts nude mice models, good uptake by the SKBR3, MCF7, and T47D tumors were found, with good tumor-to-blood and tumor to muscle ratios. Additionally, tumor lesions can be seen in γ-camera imaging. Our data suggest that based on its ability to detect HER2- and MUC1-positive breast cancer cells in vivo, 99mTc-HER2 and 99mTc-MUC1-targeted peptides may be promising tumor imaging probes and warrant further investigation." @default.
• W2970429881 created "2019-09-05" @default.
• W2970429881 creator A5009323390 @default.
• W2970429881 creator A5011476971 @default.
• W2970429881 date "2019-08-29" @default.
• W2970429881 modified "2023-10-14" @default.
• W2970429881 title "Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas" @default.
• W2970429881 cites W1573218726 @default.
• W2970429881 cites W1879197995 @default.
• W2970429881 cites W1964558905 @default.
• W2970429881 cites W1966641794 @default.
• W2970429881 cites W1971479544 @default.
• W2970429881 cites W1978739865 @default.
• W2970429881 cites W1989461833 @default.
• W2970429881 cites W1995409011 @default.
• W2970429881 cites W1996344455 @default.
• W2970429881 cites W2005490647 @default.
• W2970429881 cites W2010427283 @default.
• W2970429881 cites W2012410240 @default.
• W2970429881 cites W2014717030 @default.
• W2970429881 cites W2023685040 @default.
• W2970429881 cites W2025029381 @default.
• W2970429881 cites W2028352081 @default.
• W2970429881 cites W2028492415 @default.
• W2970429881 cites W2030704454 @default.
• W2970429881 cites W2034021751 @default.
• W2970429881 cites W2042313745 @default.
• W2970429881 cites W2062672501 @default.
• W2970429881 cites W2068344685 @default.
• W2970429881 cites W2075128452 @default.
• W2970429881 cites W2082718424 @default.
• W2970429881 cites W2090789725 @default.
• W2970429881 cites W2108965998 @default.
• W2970429881 cites W2113267914 @default.
• W2970429881 cites W2117662997 @default.
• W2970429881 cites W2125637343 @default.
• W2970429881 cites W2129537109 @default.
• W2970429881 cites W2130039391 @default.
• W2970429881 cites W2158745390 @default.
• W2970429881 cites W2158964137 @default.
• W2970429881 cites W2159539099 @default.
• W2970429881 cites W2161187689 @default.
• W2970429881 cites W2318658628 @default.
• W2970429881 cites W2320248812 @default.
• W2970429881 cites W2333749640 @default.
• W2970429881 cites W2334781576 @default.
• W2970429881 cites W2430440408 @default.
• W2970429881 cites W2510181658 @default.
• W2970429881 cites W2565744488 @default.
• W2970429881 cites W2577593852 @default.
• W2970429881 cites W2578340824 @default.
• W2970429881 cites W2725185907 @default.
• W2970429881 cites W2797503545 @default.
• W2970429881 cites W2809426230 @default.
• W2970429881 cites W28705092 @default.
• W2970429881 cites W2896378740 @default.
• W2970429881 cites W2945233873 @default.
• W2970429881 cites W2952784973 @default.
• W2970429881 doi "https://doi.org/10.3390/molecules24173142" @default.
• W2970429881 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6749314" @default.
• W2970429881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31470531" @default.
• W2970429881 hasPublicationYear "2019" @default.
• W2970429881 type Work @default.
• W2970429881 sameAs 2970429881 @default.
• W2970429881 citedByCount "20" @default.
• W2970429881 countsByYear W29704298812018 @default.
• W2970429881 countsByYear W29704298812020 @default.
• W2970429881 countsByYear W29704298812021 @default.
• W2970429881 countsByYear W29704298812022 @default.
• W2970429881 countsByYear W29704298812023 @default.
• W2970429881 crossrefType "journal-article" @default.
• W2970429881 hasAuthorship W2970429881A5009323390 @default.
• W2970429881 hasAuthorship W2970429881A5011476971 @default.
• W2970429881 hasBestOaLocation W29704298811 @default.
• W2970429881 hasConcept C118646709 @default.
• W2970429881 hasConcept C121608353 @default.
• W2970429881 hasConcept C126322002 @default.
• W2970429881 hasConcept C143998085 @default.
• W2970429881 hasConcept C147483822 @default.
• W2970429881 hasConcept C203014093 @default.
• W2970429881 hasConcept C2776662205 @default.
• W2970429881 hasConcept C2777421810 @default.
• W2970429881 hasConcept C2777701055 @default.
• W2970429881 hasConcept C2780427987 @default.
• W2970429881 hasConcept C2781230642 @default.
• W2970429881 hasConcept C502942594 @default.
• W2970429881 hasConcept C530470458 @default.
• W2970429881 hasConcept C71924100 @default.
• W2970429881 hasConceptScore W2970429881C118646709 @default.
• W2970429881 hasConceptScore W2970429881C121608353 @default.
• W2970429881 hasConceptScore W2970429881C126322002 @default.
• W2970429881 hasConceptScore W2970429881C143998085 @default.
• W2970429881 hasConceptScore W2970429881C147483822 @default.
• W2970429881 hasConceptScore W2970429881C203014093 @default.
• W2970429881 hasConceptScore W2970429881C2776662205 @default.
• W2970429881 hasConceptScore W2970429881C2777421810 @default.
• W2970429881 hasConceptScore W2970429881C2777701055 @default.
• W2970429881 hasConceptScore W2970429881C2780427987 @default.

• next